Clever Leaves, an international cannabis company with main operations in Colombia, announced Thursday that it obtained EU-Good Manufacturing Practice certification “to produce Active Pharmaceutical Ingredients (API), semi-finished and finished cannabis products for medical purposes” in its Colombian facilities.
The certification is “expected to broaden Clever Leaves’ ability to serve international markets,” the press release said.
“Any manufacturer of medicines intended for the EU market, no matter where in the world it is located, must comply with GMP,” the European Medicines Agency website says.
A spokesperson of the company told Marijuana Business Daily that the Croatian Agency for Medicinal Products and Medical Devices inspected Clever Leaves facilities in Colombia in January, issuing the certificate – verified by MJBizDaily – this week.
Only a handful of cannabis facilities in the world have EU-GMP certification to manufacture extracts.
MJBizDaily isn’t aware of any other cannabis producer that has publicly announced obtaining EU-GMP certification for a Latin American facility, and no cannabis facility on the continent can be found in the publicly available official EudraGMDP database of the European Union.
While exports of high-THC medical flower to the EU without EU-GMP certification are possible under certain conditions, Colombia does not allow the exportation of flower for commercial purposes.
This leaves Colombian producers little room for maneuver other than obtaining the EU certification if they want to export medicinal extracts manufactured from Colombia to the EU.
Clever Leaves is aiming to list on the Nasdaq stock market.
Pure Cannabis Hemp Oil
- Pure CBD Tincture, derived from organic, US-harvested hemp, lab-tested for quality.
- Clinically proven therapeutic effects.
- Relieves anxiety and stress
- Eliminates chronic pain and aches
- Regulates mood and sleep patterns
- Enhances focus and clarity
george scorsis
Originally posted on via Cannabis Industry News
No comments:
Post a Comment